System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Farid El Hajbi is an expert in Oncology at Centre Oscar Lambret (France). As of September 2026, ScienceLeadR ranks Farid El Hajbi in the top 1% of experts worldwide for Carcinoma, and in the top 1% of experts in France for Esophageal Neoplasms. Farid El Hajbi has authored 57 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 2 of them ongoing. SLR score: 353 (community average: 125). How the SLR is computed.

LeadR Profile

Farid El Hajbi Centre Oscar Lambret France
353 ScienceLeadR Reputation 353

Unlock

Register Login
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2015 - 2026
Source: PubMed

Centre Oscar Lambret

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 57

Citations

Citations: 3 544 1st author: 0 Last author: 1 Unique author: 0

Main journals

J Clin Oncol 11
Ann Oncol 8
Eur J Cancer 5
BMC Cancer 3
Dig Liver Dis 3

Best Journals

J Clin Oncol 6
Lancet Oncol 3
BMJ 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.
PMID 41774886 — cells, lung, drug therapy, nivolumab, therapeutics, ipilimumab, carcinoma, neuroendocrine, chemotherapy		J Clin Oncol Top journal20261
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
PMID 40378359 — pancreatic neoplasms, neoplasms, drug therapy, therapeutics, medical oncology, chemotherapy		J Clin Oncol Top journal20250
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
PMID 38573643 — leucovorin, esophagogastric junction, neoplasms, adenocarcinoma, drug therapy, immune checkpoint inhibitors, therapeutics, chemotherapy		JAMA Oncol202412
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
PMID 38547895 — cells, progression-free survival, docetaxel, anus neoplasms, carcinoma, squamous cell, neoplasms, fluorouracil, drug-related side effects and adverse reactions, therapeutics		Lancet Oncol Top journal202420
Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).
PMID 37635055 — digestive system diseases, neoplasms, drug therapy, immunotherapy, diagnosis, therapeutics, esophageal neoplasms, chemotherapy		Dig Liver Dis20238

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 11
Phase 3 7

By status:

Completed 11
Terminated 3
Active not recruiting 2
Recruiting 2

By type:

Interventional 18

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 2
multicentricup10 15

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Master rollover study to provide continued access to and assess long term safety of the study drugs
2023-506330-73-00 — growth, safety, pharmaceutical preparations, neoplasms, therapeutics		Phase 3Recruiting2024
Anti PD 1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma
NCT04719988 — radiotherapy, cells, laboratories, blood, docetaxel, anus neoplasms, carcinoma, squamous cell, neoplasms, biopsy, drug therapy, fluorouracil, immunotherapy, chemoradiotherapy, specimen handling, biological monitoring, alphapapillomavirus, edetic acid, dna, temperature, prognosis, plasma, chemotherapy, human papillomavirus viruses, carcinoma		Phase 2Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS